NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a company developing proprietary carbohydrate-based therapeutic compounds to treat serious diseases such as cancer and fibrosis, has named Scott L. Friedman, M.D., to its Scientific Advisory Board.
